Syndax Pharmaceuticals
NASDAQ: SNDXWaltham, US · Incorporated in Delaware · 333 employees on LinkedIn · 7 known investors
Find your way into Syndax Pharmaceuticals
23 people in our graph share verified history with the Syndax Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.
Briggs Morrisonunlockedknows Arlene Morris · together at Syndax Pharmaceutical (overlapped)
knows the team · via Dimension Therapeutics
×2knows the team · via Viridian Therapeutics, Inc.
×2knows the team · via Edgewise Therapeutics
knows the team · via Affymax
knows the team · via NEOVACS SA
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.
Founders & leadership
JP
John PalliesinChief Financial Officer2013–2016
AM
Arlene MorrisinExecutiveShe brings experience in business development, investor relations, and commercial development across pharmaceutical, biotechnology, medical device, vaccine, and gene therapy sectors, along with nonprofit board service.
MA
Michael A. MetzgerinChief Executive OfficerMichael Metzger is Chief Executive Officer of Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company developing cancer therapies. He has prior experience as a life sciences executive at biotechnology companies spanning development through public markets, as well as investment background in pharmaceutical licensing and mergers and acquisitions.
KA
Keith A. GoldaninChief Financial OfficerKeith Goldan is Chief Financial Officer of Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company developing cancer therapies. He brings 30 years of executive experience across pharmaceutical, biotechnology, and medical device companies, with expertise spanning corporate development, capital markets, and public company financial management, and holds an MBA from Wharton.
Board
DP
IR
Ivor RoystonBoard director
LE
Luke Evnin, Ph.D.Board director
KK
Kim Kamdar, Ph.DBoard director
GW
George W Sledge, Jr. M.D.Board director
FE
Fabrice Egros, Ph.D.Board director
RP
Richard P SheaBoard director
Investors · 7
Reported raises · per SEC filings
Form D private placements$93.2M disclosed across 5 rounds · 2014–2015
▶$61.3MraisedAug 2015 · 19 investors · PharmaceuticalsRule 506(b)
▶$61.3MraisedAug 2015 · 19 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dennis PodlesakDirector
- Fabrice Egros, Ph.D.Director
- Michael MetzgerExecutive Officer
- Kim Kamdar, Ph.DDirector
- Luke Evnin, Ph.D.Director
- Ivor Royston, M.D.Director
- George W Sledge, Jr., M.D.Director
- John PalliesExecutive Officer
- Richard P SheaDirector
- Henry ChenDirector
- Briggs Morrison, M.D.Executive Officer, Director
- Offering amount
- $61.3M
- Amount sold
- $61.3M
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$24MraisedJun 2015 · 12 investors · PharmaceuticalsRule 506(b)
▶$24MraisedJun 2015 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- George W Sledge, Jr. M.D.Director
- Richard P SheaDirector
- Ivor RoystonDirector
- Fabrice Egros, Ph.D.Director
- Luke Evnin, Ph.D.Director
- Henry ChenDirector
- Michael MetzgerExecutive Officer
- John PalliesExecutive Officer
- Dennis PodlesakDirector
- Kim Kamdar, Ph.DDirector
- Offering amount
- $45.2M
- Amount sold
- $24M
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.9MraisedSep 2014 · 10 investors · PharmaceuticalsRule 506(b)
▶$4.9MraisedSep 2014 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Fabrice Egros, Ph.D.Director
- George W Sledge, Jr. M.D.Director
- Arlene MorrisExecutive Officer, Director
- John PalliesExecutive Officer
- Dennis PodlesakDirector
- Kim Kamdar, Ph.DDirector
- Ivor RoystonDirector
- Luke Evnin, Ph.D.Director
- Richard P SheaDirector
- Offering amount
- $5M
- Amount sold
- $4.9M
- First sale
- Sep 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.7MraisedFeb 2014 · 3 investors · PharmaceuticalsRule 506(b)
▶$1.7MraisedFeb 2014 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dennis PodlesakDirector
- Ivor RoystonDirector
- John PalliesExecutive Officer
- Luke Evnin, Ph.D.Director
- George W Sledge, Jr. M.D.Director
- Fabrice Egros, Ph.D.Director
- Arlene MorrisExecutive Officer, Director
- Richard P SheaDirector
- Kim Kamdar, Ph.DDirector
- Offering amount
- $1.7M
- Amount sold
- $1.7M
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedFeb 2014 · 4 investors · PharmaceuticalsRule 506(b)
▶$1.3MraisedFeb 2014 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dennis PodlesakDirector
- Luke Evnin, Ph.D.Director
- Ivor RoystonDirector
- Arlene MorrisExecutive Officer, Director
- Kim Kamdar, Ph.DDirector
- Fabrice Egros, Ph.D.Director
- John PalliesExecutive Officer
- Richard P SheaDirector
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- First sale
- Jan 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$208.5Mvaluation at IPOMar 2016 · $12.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Syndax (SNDX) Q2 2026 Earnings Call Transcript - AOLaol.com · Aug 2026
Syndax Pharmaceuticals Q2 2026 revenue rises, loss narrows | SNDX Quarterly Report (10-Q)stocktitan.net · Aug 2026Frequently asked questions
- What does Syndax Pharmaceuticals do?
- Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.
- Who are Syndax Pharmaceuticals's investors?
- Syndax Pharmaceuticals's investors include Foresite Capital, Pappas Capital, Sofinnova Ventures, venBio Partners, BlackRock, Domain Associates, MPM BioImpact.
- How much funding has Syndax Pharmaceuticals raised?
- Syndax Pharmaceuticals has disclosed $93.2M raised across 5 rounds.
- Where is Syndax Pharmaceuticals headquartered?
- Syndax Pharmaceuticals is headquartered in Waltham, US.